- Home
- HCWB vs UCAR Comparison
HCWB vs UCAR Comparison
Compare HCWB & UCAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- UCAR
- Stock Information
- Founded
- HCWB 2018
- UCAR 2013
- Country
- HCWB United States
- UCAR China
- Employees
- HCWB N/A
- UCAR N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- UCAR Retail-Auto Dealers and Gas Stations
- Sector
- HCWB Health Care
- UCAR Consumer Discretionary
- Exchange
- HCWB Nasdaq
- UCAR Nasdaq
- Market Cap
- HCWB 17.2M
- UCAR 23.3M
- IPO Year
- HCWB 2021
- UCAR 2023
- Fundamental
- Price
- HCWB $0.35
- UCAR $2.70
- Analyst Decision
- HCWB
- UCAR
- Analyst Count
- HCWB 0
- UCAR 0
- Target Price
- HCWB N/A
- UCAR N/A
- AVG Volume (30 Days)
- HCWB 281.9K
- UCAR 42.3K
- Earning Date
- HCWB 03-31-2025
- UCAR 03-26-2025
- Dividend Yield
- HCWB N/A
- UCAR N/A
- EPS Growth
- HCWB N/A
- UCAR N/A
- EPS
- HCWB N/A
- UCAR N/A
- Revenue
- HCWB $3,495,990.00
- UCAR $4,273,899.00
- Revenue This Year
- HCWB $229.19
- UCAR N/A
- Revenue Next Year
- HCWB N/A
- UCAR N/A
- P/E Ratio
- HCWB N/A
- UCAR N/A
- Revenue Growth
- HCWB 22.27
- UCAR 473.55
- 52 Week Low
- HCWB $0.21
- UCAR $2.31
- 52 Week High
- HCWB $2.52
- UCAR $9.43
- Technical
- Relative Strength Index (RSI)
- HCWB 46.07
- UCAR 34.95
- Support Level
- HCWB $0.33
- UCAR $2.50
- Resistance Level
- HCWB $0.38
- UCAR $2.82
- Average True Range (ATR)
- HCWB 0.03
- UCAR 0.28
- MACD
- HCWB -0.00
- UCAR 0.12
- Stochastic Oscillator
- HCWB 33.18
- UCAR 7.03
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufactory and sales; battery swapping services and sourcing services. The company as a broker engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.